ERBB2 and non-small cell lung carcinoma: In July 2020, a phase II clinical trial (RAIN-701 trial, NCT03805841) evaluated 11 HER2-mutant NSCLC patients who failed platinum-based chemotherapy to be treated with tarloxotinib.